Each filer's latest filing for 501575104 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
FMR LLC
13G/A
|
14.3% |
5/6/2026
Event 3/31/2026
|
||
| FMR LLC | 14.3% | |||
| Abigail P. Johnson | 14.3% | |||
|
Baker Bros. Advisors LP
13D/A
|
10.9% |
12/11/2025
Event 12/9/2025
|
||
| Baker Bros. Advisors LP | 10.9% | |||
| Baker Bros. Advisors (GP) LLC | 10.9% | |||
| Julian C. Baker | 10.9% | |||
| Felix J. Baker | 10.9% | |||
| Price T Rowe Associates Inc /MD/ 13G/A | 10.7% |
9/8/2026
Event 8/31/2026
|
||
| T. Rowe Price Investment Management, Inc. 13G | 6.7% |
5/15/2026
Event 3/31/2026
|
||
| BlackRock, Inc. 13G/A | 6.6% |
10/27/2026
Event 9/30/2026
|
||
|
Biotechnology Value Fund L P
13D/A
|
6.3% |
6/26/2026
Event 6/26/2026
|
||
| Biotechnology Value Fund L P | 3.3% | |||
| BVF I GP LLC | 3.3% | |||
| Biotechnology Value Fund II LP | 2.6% | |||
| BVF II GP LLC | 2.6% | |||
| Biotechnology Value Trading Fund OS LP | 0.4% | |||
| BVF Partners OS Ltd. | 0.4% | |||
| BVF GP Holdings LLC | 5.8% | |||
| BVF Partners L P/IL | 6.3% | |||
| BVF Inc/IL | 6.3% | |||
| Lampert Mark N | 6.3% | |||
| Hrustanovic Gorjan | 0.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
Wellington Management Group LLP
13G/A
|
4.8% |
5/15/2026
Event 3/31/2026
|
||
| Wellington Management Group LLP | 4.8% | |||
| Wellington Group Holdings LLP | 4.8% | |||
| Wellington Investment Advisors Holdings LLP | 4.8% | |||
|
Atlas Venture Fund X, L.P.
13G/A
|
2.9% |
8/13/2026
Event 6/30/2026
|
||
| Atlas Venture Fund X, L.P. | 2.9% | |||
| Atlas Venture Associates X, L.P. | 2.9% | |||
| Atlas Venture Associates X, LLC | 2.9% | |||
| Atlas Venture Opportunity Fund I, L.P. | 0.6% | |||
| Atlas Venture Associates Opportunity I, L.P. | 0.6% | |||
| Atlas Venture Associates Opportunity I, LLC | 0.6% | |||
| Vanguard Group Inc 13G/A | 0% |
3/27/2026
Event 3/13/2026
|
||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 137 | 22.6 M | $2.52B |
| 2026 Q2 | 286 | 97.0 M | $11.1B |
| 2026 Q1 | 261 | 96.3 M | $8.01B |
| 2025 Q4 | 260 | 90.0 M | $7.00B |
| 2025 Q3 | 215 | 80.9 M | $4.58B |
| 2025 Q2 | 213 | 78.8 M | $3.44B |
| 2025 Q1 | 178 | 72.9 M | $2.00B |
| 2024 Q4 | 182 | 71.7 M | $2.88B |
| 2024 Q3 | 177 | 69.1 M | $3.27B |
| 2024 Q2 | 158 | 67.4 M | $2.01B |
| 2024 Q1 | 165 | 67.2 M | $2.70B |
| 2023 Q4 | 138 | 60.5 M | $1.54B |
| 2023 Q3 | 123 | 57.4 M | $797M |
| 2023 Q2 | 130 | 58.4 M | $1.34B |
| 2023 Q1 | 130 | 56.9 M | $1.68B |
| 2022 Q4 | 125 | 56.1 M | $1.40B |
| 2022 Q3 | 130 | 52.8 M | $1.15B |
| 2022 Q2 | 104 | 49.4 M | $974M |
| 2022 Q1 | 131 | 45.7 M | $1.93B |
| 2021 Q4 | 131 | 43.5 M | $2.76B |
| 2021 Q3 | 118 | 34.6 M | $2.04B |
| 2021 Q2 | 113 | 26.5 M | $1.29B |
| 2021 Q1 | 99 | 22.8 M | $887M |
| 2020 Q4 | 77 | 20.3 M | $1.25B |
| 2020 Q3 | 53 | 16.8 M | $543M |